(-1.57%) 5 035.69 points
(-1.49%) 37 816 points
(-2.04%) 15 658 points
(-0.94%) $81.16
(-2.06%) $1.950
(-0.47%) $2 292.10
(-0.24%) $26.59
(-0.41%) $944.30
(0.13%) $0.938
(0.28%) $11.13
(0.16%) $0.802
(0.00%) $93.45
Live Chart Being Loaded With Signals
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries...
Stats | |
---|---|
今日成交量 | 6.42M |
平均成交量 | 0.00 |
市值 | 2.46B |
EPS | HKD0 ( 2024-03-29 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -3.09 |
ATR14 | HKD0.268 (4.77%) |
音量 相关性
Venus MedTech HangZhou 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Venus MedTech HangZhou 相关性 - 货币/商品
Venus MedTech HangZhou 财务报表
Annual | 2023 |
营收: | HKD491.37M |
毛利润: | HKD389.21M (79.21 %) |
EPS: | HKD-1.650 |
FY | 2023 |
营收: | HKD491.37M |
毛利润: | HKD389.21M (79.21 %) |
EPS: | HKD-1.650 |
FY | 2022 |
营收: | HKD406.46M |
毛利润: | HKD314.00M (77.25 %) |
EPS: | HKD-2.56 |
FY | 2021 |
营收: | HKD415.86M |
毛利润: | HKD324.34M (77.99 %) |
EPS: | HKD-0.850 |
Financial Reports:
No articles found.
Venus MedTech HangZhou
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。